According to the multi-year agreement, Synovate will license aggregated and de-identified data collected from users of Impac’s oncology EMR and cancer registry systems, with the intention of delivering accurate information to pharmaceutical and biotech companies.
Michael Spedding, CEO of Synovate Healthcare, added that the alliance will digitalize the company’s existing paper-based data collection methods to increase the speed and accuracy of received data.
Synovate will also gain access to the electronic data of over 2.3 million cases resident in the Impac NODB and augmented by Impac’s cancer-directed software products and services.
